Silence Therapeutics (SLN) Equity Average: 2019-2025
Historic Equity Average for Silence Therapeutics (SLN) over the last 7 years, with Sep 2025 value amounting to $84.1 million.
- Silence Therapeutics' Equity Average was N/A to $84.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.1 million, marking a year-over-year change of. This contributed to the annual value of $78.0 million for FY2024, which is 217.02% up from last year.
- Per Silence Therapeutics' latest filing, its Equity Average stood at $84.1 million for Q3 2025, which was down 18.70% from $103.4 million recorded in Q2 2025.
- Silence Therapeutics' Equity Average's 5-year high stood at $130.4 million during Q4 2024, with a 5-year trough of $8.4 million in Q1 2022.
- Over the past 3 years, Silence Therapeutics' median Equity Average value was $96.4 million (recorded in 2024), while the average stood at $92.3 million.
- Per our database at Business Quant, Silence Therapeutics' Equity Average soared by 288.14% in 2024 and then tumbled by 38.05% in 2025.
- MRQ analysis of 5 years shows Silence Therapeutics' Equity Average stood at $17.0 million in 2021, then tumbled by 50.52% to $8.4 million in 2022, then surged by 173.37% to $23.0 million in 2023, then skyrocketed by 466.11% to $130.4 million in 2024, then crashed by 35.48% to $84.1 million in 2025.
- Its Equity Average was $84.1 million in Q3 2025, compared to $103.4 million in Q2 2025 and $123.4 million in Q1 2025.